International Journal of General Medicine (Jan 2022)
MiR-195-3p is a Novel Prognostic Biomarker Associated with Immune Infiltrates of Lung Adenocarcinoma
Abstract
Yi Lao,1 Taidong Li,2 Xin Xie,1 Kangbiao Chen,1 Ming Li,1 Lu Huang1 1The Fourth Department of Medical Oncology, Central Hospital of Guangdong Nongken, Zhanjiang Cancer Hospital, Zhanjiang, Guangdong, 524002, People’s Republic of China; 2Department of Thoracic Surgery, Central Hospital of Guangdong Nongken, Zhanjiang Cancer Hospital, Zhanjiang, Guangdong, 524002, People’s Republic of ChinaCorrespondence: Lu HuangThe Fourth Department of Medical Oncology, Central Hospital of Guangdong Nongken, Zhanjiang Cancer Hospital, No. 2 Mid Renmin Avenue, Zhanjiang, 524002, Guangdong, People’s Republic of ChinaTel +86-0759-2633696Email [email protected]: MicroRNA-195-3p (miR-195-3p) plays an important role in some tumors, but its role in LUAD is unclear. This study explored the expression of miR-195-3p in LUAD and the relationship between the expression of miR-195-3p and the clinical and prognostic characteristics of LUAD patients.Methods: MiR-195-3p expression and clinical information of LUAD patients were obtained from The Cancer Genome Atlas (TCGA). Kruskal–Wallis test, Wilcoxon signed rank test, logistic regression, and Cox regression were used to assess the relationship between the expression level of miR-195-3p and clinical features in LUAD tissues. Kaplan–Meier survival curves were used to analyze the effect of miR-195-3p expression levels on the prognosis of LUAD patients. Target genes of miR-195-3p were predicted by several software. GO (Gene Ontology), KEGG (Kyoto Encyclopedia of Genes and Genomes), and immune infiltration analysis were used to analyze the possible regulatory network of miR-195-3p.Results: Compared with normal lung tissue, miR-195-3p is down expressed in LUAD tissue (P < 0.001). The low miR-195-3p expression in LUAD was significantly associated with N stage (P = 0.046), pathologic stage (P = 0.011), and gender (P = 0.010). Low miR-195-3p expression predicted a poorer overall survival (HR: 0.60; 95% CI: 0.45– 0.81; P = 0.001) and disease-specific survival (HR: 0.55; 95% CI: 0.37– 0.80; P = 0.002). The expression of miR-195-3p (HR: 0.488; 95% CI: 0.304– 0.784; P = 0.003) was independently correlated with OS in LUAD patients. High expression of miR-195-3p genes, including ABCC2, AGMAT, ARNTL2, ATP6V0A4, CDC25A, CDK1, FAM111B, GJB2, GRIP1, HMGA2, HOXA9, KIF14, SYT2, and TFAP2A, were associated with poor OS in LUAD. GO and KEGG analysis suggested that miR-195-3p was related to the phagosome pathway. MiR-195-3p may promote the function of B cells, dendritic cells, eosinophils, immature dendritic cells, macrophages, Mast cells, NK cells, plasmacytoid dendritic cells, and follicular helper T cells.Conclusion: Low miR-195-3p expression is significantly associated with poor survival in LUAD, which may be a promising prognostic biomarker for LUAD.Keywords: lung adenocarcinoma, miR-195-3p, gene expression, prognosis, immune infiltration, biomarker
